A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

1 (33%) 4 (80%) 5 (62%) 4 (50%) Anemia 2 (67%) 3 (60%) 5 (62%) 2 (25%) Lymphopenia 1 (33%) 1 (20%) 2 (25%) 2 (25%) Neutropenia 0 2 (40%) 2 (25%) 1 (12%) Non-Hematologic Fatigue 3 (100%) 2 (40%) 5 (62%) 1 (12%) Nausea 2 (67%) 2 (40%) 4 (50%) 1 (12%) Constipation 1 (33%) 2 (40%) 3 (38%) 0 Neuropathy Peripheral 2 (67%) 1 (20%) 3 (38%) 0 Abdominal Pain 0 2 (40%) 2 (25%) 1 (12%) Back Pain 1 (33%) 1 (20%) 2 (25%) 0 Blood Creatinine Increased 1 (33%) 1 (20%) 2 (25%) 0 Contusion 0 2 (40%) 2 (25%) 0 Hyperglycemia 1 (33%) 1 (20%) 2 (25%) 0 Insomnia 2 (67%) 0 2 (25%) 0 Pyrexia 1 (33%) 1 (20%) 2 (25%) 0 Rectal Hemorrhage 1 (33%) 1 (20%) 2 (25%) 0 Vomiting 0 2 (40%) 2 (25%) 1 (12%)